Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 13/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3054237 | 1.00 | TACR1 (0.47) | TACR1TRPM8CTSKKCNH2HDAC8 | |
| SCHEMBL3057806 | 0.91 | TACR1 (0.46) | TACR1TRPM8CTSKKCNH2GPBAR1 | |
| SCHEMBL3060715 | 0.91 | TACR1 (0.46) | TACR1TRPM8CTSKKCNH2GPBAR1 | |
| SCHEMBL3061060 | 0.86 | TACR1 (0.52) | TACR1TRPM8GPBAR1 | |
| SCHEMBL3057776 | 0.86 | TACR1 (0.52) | TACR1TRPM8GPBAR1 | |
| SCHEMBL3051048 | 0.86 | TACR1 (0.52) | TACR1TRPM8GPBAR1 | |
| SCHEMBL3058232 | 0.78 | TRPM8 (0.49) | TACR1TRPM8KCNH2HDAC8PPARG | |
| SCHEMBL3060247 | 0.78 | TRPM8 (0.49) | TACR1TRPM8KCNH2HDAC8PPARG | |
| SCHEMBL3048426 | 0.76 | MEN1 (0.46) | TACR1TRPM8PPARGPPARA | |
| SCHEMBL3060312 | 0.76 | MEN1 (0.46) | TACR1TRPM8PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | CYP11B2, CYP11B1, BBC3 | TACR1 1055/4885TRPM8 1326/4885CTSK 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.